Your browser doesn't support javascript.
loading
Atypical Cogan's Syndrome Mimicking Giant Cell Arteritis Successfully Treated with Early Administration of Tocilizumab.
Hara, Kazusato; Umeda, Masataka; Segawa, Keiko; Akagi, Midori; Endo, Yushiro; Koga, Tomohiro; Kawashiri, Shin-Ya; Ichinose, Kunihiro; Nakamura, Hideki; Maeda, Takahiro; Kawakami, Atsushi.
Afiliación
  • Hara K; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
  • Umeda M; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
  • Segawa K; Medical Education Development Center, Nagasaki University Hospital, Japan.
  • Akagi M; Department of General Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.
  • Endo Y; Department of Radiological Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan.
  • Koga T; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
  • Kawashiri SY; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
  • Ichinose K; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
  • Nakamura H; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
  • Maeda T; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
  • Kawakami A; Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Intern Med ; 61(8): 1265-1270, 2022 Apr 15.
Article en En | MEDLINE | ID: mdl-34615818
A 49-year-old Japanese man with a 2-month history of a fever, headache, and bilateral conjunctival hyperemia was admitted. His condition fulfilled the giant cell arteritis classification criteria (new headache, temporal artery tenderness, elevated ESR) and atypical Cogan's syndrome (CS) with scleritis and sensorineural hearing loss (SNHL). The interleukin (IL)-6 serum level was extremely high. Two weeks after his insufficient response of SNHL and scleritis to oral prednisolone, we administered tocilizumab (TCZ); rapid improvements in scleritis and SNHL occurred. Early IL-6 target therapy can help prevent irreversible CS-induced sensory organ damage.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Arteritis de Células Gigantes / Escleritis / Síndrome de Cogan / Pérdida Auditiva Sensorineural / Queratitis Tipo de estudio: Diagnostic_studies / Etiology_studies Límite: Humans / Male / Middle aged Idioma: En Revista: Intern Med Asunto de la revista: MEDICINA INTERNA Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Arteritis de Células Gigantes / Escleritis / Síndrome de Cogan / Pérdida Auditiva Sensorineural / Queratitis Tipo de estudio: Diagnostic_studies / Etiology_studies Límite: Humans / Male / Middle aged Idioma: En Revista: Intern Med Asunto de la revista: MEDICINA INTERNA Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón